Loading the section…
The price of Rigel Pharmaceuticals, Inc. (RIGL) on October 9, 2026 is 49.08 USD, +0.74% on the day. Over 52 weeks the stock traded between 24.95 USD and 52.24 USD; the price now sits 88% of the way up that range. Over the past year the price changed by +70.65%. The P/E ratio is 2.5, which is below the sector median (25.0). Market capitalization is 898.70 million USD, rank 116 among 372 stocks of the same industry with a known capitalization.
Closing prices for 9 October 2026
Next earnings report: 3 November 2026 · Earnings calendar
Change over the period shown (line colour): +82.93 %
Rigel Pharmaceuticals, Inc. trades on Nasdaq under the ticker RIGL. The company belongs to the Health care sector. The trading history on this page starts on 22 August 2016.
Over the past 52 weeks RIGL has traded between 24.95 $ and 52.24 $. As of 9 October 2026 the price stood 88.42 % of the way from the 52-week low to the high.
Over one year RIGL shares rose 70.65 %; over six months they rose 68.08 %. Volatility over 90 days is 40.46 %. Dividends are not included: this is price change only, as of 9 October 2026.
RIGL trades at a price-to-earnings ratio of 2.5, below the sector median of 25.0. Price to sales is 3.0, below the sector median of 4.0. Price to book is 2.2, below the sector median of 2.5. Calculated from reports for the period ending 31 March 2026.
| Date | Open | High | Low | Close | Volume, shares |
|---|---|---|---|---|---|
| 9 October 2026 | 48.60 | 50.49 | 48.60 | 49.08 | 279,400 |
| 8 October 2026 | 47.33 | 48.89 | 46.56 | 48.72 | 216,800 |
| 7 October 2026 | 45.64 | 48.15 | 45.22 | 47.99 | 232,600 |
| 6 October 2026 | 48.18 | 48.18 |
The series is stated in the current share scale after splits; dividends are not included in the price
Based on the last 12 months of reports, through 31 March 2026
The sector median covers every company in the sector on the US market, loss-making ones included.
Address:611 GATEWAY BOULEVARD, SUITE 900, SOUTH SAN FRANCISCO, CA, 94080, US
Rigel Pharmaceuticals, Inc. reported revenue of 300M $ and net income of 364M $ over the last four quarters. Net margin is 121.51 %. Revenue changed by +47.61 % year over year. Earnings per share are 19.29 $. Market capitalisation is 899M $.
RIGL has a return on equity of 91.08 %, above the sector median of −41.68 %. Return on assets is 72.18 %, above the sector median of −32.11 %. Operating margin is 41.56 %, above the sector median of −26.84 %.
| 1.2B |
| PFEPfizer, Inc. | 28.28 | +1.65 % | 922M |
| ABTAbbott Laboratories | 99.60 | +1.13 % | 921M |
| BMYBristol-Myers Squibb Company | 59.12 | −0.77 % | 714M |
| REGNRegeneron Pharmaceuticals, Inc. | 746.54 | +0.94 % | 555M |
| 45.93 |
| 46.11 |
| 202,600 |
| 5 October 2026 | 47.02 | 48.83 | 46.93 | 47.79 | 391,600 |
| 2 October 2026 | 47.66 | 48.00 | 46.45 | 47.15 | 185,700 |
| 1 October 2026 | 48.05 | 48.87 | 46.81 | 46.97 | 235,000 |
| 30 September 2026 | 49.27 | 49.70 | 47.80 | 48.15 | 252,200 |
| 29 September 2026 | 49.38 | 49.70 | 48.61 | 48.89 | 182,200 |
| 28 September 2026 | 48.16 | 49.65 | 47.49 | 49.36 | 180,900 |
| 25 September 2026 | 48.23 | 48.53 | 47.20 | 48.18 | 204,900 |
| 24 September 2026 | 47.87 | 48.14 | 47.00 | 47.89 | 143,800 |
| 23 September 2026 | 48.62 | 48.69 | 46.91 | 48.13 | 151,400 |
| 22 September 2026 | 47.50 | 49.02 | 47.23 | 48.82 | 242,900 |
| 21 September 2026 | 47.13 | 47.51 | 46.49 | 47.09 | 164,800 |
| 18 September 2026 | 45.54 | 46.99 | 45.24 | 46.64 | 939,600 |
| 17 September 2026 | 45.25 | 46.27 | 45.14 | 45.85 | 165,700 |
| 16 September 2026 | 44.14 | 45.37 | 43.78 | 44.48 | 226,400 |
| 15 September 2026 | 45.14 | 46.26 | 44.22 | 44.36 | 269,900 |
| 14 September 2026 | 47.32 | 47.53 | 44.96 | 45.35 | 335,800 |